Mutant p53 Activities in Mouse Tumor Models
1.6 هزار بار بازدید -
2 سال پیش
-
Air date: Wednesday, December 7,
Air date: Wednesday, December 7, 2022, 3PM
Description: NIH Director’s Wednesday Afternoon Lecture Series [WALS]
Margaret Pittman Lecture
This is the annual WALS–Pittman lecture, but rescheduled from March 2022. Guillermina (Gigi) Lozano is a renowned geneticist recognized for her studies of the p53 tumor suppressor pathway. This pathway is undermined in a large percent of human cancers via mutations and deletions of p53. Her laboratory identified a transcriptional activation function for p53. Using mouse models, her team characterized the physiological importance of Mdm2 and Mdm4 proteins as potent inhibitors of p53. The Mdm proteins are over expressed in many cancers that lack p53 mutations presenting an alternate mechanism of eliminating p53 activity. Other mouse models inheriting the most common p53 mutations revealed gain-of-function phenotypes that drive metastases. Mutation of the p53 gene is a critical event in the elaboration of many tumors of diverse origin. The p53 protein is activated in response to DNA damage, serving as a checkpoint in the elimination or repair of cells with damaged DNA. Alterations in components of the p53 pathway, such as amplification of the Mdm2 gene, which encodes a p53 inhibitor, also contribute to tumorigenesis. The overall goal of my laboratory is to understand the signals that regulate the p53 pathway and the consequences of expressing wild-type or mutant p53.
For more information go to https://oir.nih.gov/wals
Author:
Guillermina Lozano, Ph.D., University of Texas MD Anderson Cancer Center
Permanent link: https://videocast.nih.gov/watch=46003
Description: NIH Director’s Wednesday Afternoon Lecture Series [WALS]
Margaret Pittman Lecture
This is the annual WALS–Pittman lecture, but rescheduled from March 2022. Guillermina (Gigi) Lozano is a renowned geneticist recognized for her studies of the p53 tumor suppressor pathway. This pathway is undermined in a large percent of human cancers via mutations and deletions of p53. Her laboratory identified a transcriptional activation function for p53. Using mouse models, her team characterized the physiological importance of Mdm2 and Mdm4 proteins as potent inhibitors of p53. The Mdm proteins are over expressed in many cancers that lack p53 mutations presenting an alternate mechanism of eliminating p53 activity. Other mouse models inheriting the most common p53 mutations revealed gain-of-function phenotypes that drive metastases. Mutation of the p53 gene is a critical event in the elaboration of many tumors of diverse origin. The p53 protein is activated in response to DNA damage, serving as a checkpoint in the elimination or repair of cells with damaged DNA. Alterations in components of the p53 pathway, such as amplification of the Mdm2 gene, which encodes a p53 inhibitor, also contribute to tumorigenesis. The overall goal of my laboratory is to understand the signals that regulate the p53 pathway and the consequences of expressing wild-type or mutant p53.
For more information go to https://oir.nih.gov/wals
Author:
Guillermina Lozano, Ph.D., University of Texas MD Anderson Cancer Center
Permanent link: https://videocast.nih.gov/watch=46003
2 سال پیش
در تاریخ 1401/09/17 منتشر شده
است.
1,616
بـار بازدید شده